PDGFRα: A new therapeutic target in the treatment of hepatocellular carcinoma?

Abdul M. Oseini, Lewis Rowland Roberts

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background: Hepatocellular carcinoma (HCC) develops most often in a background of chronic inflammatory liver injury from viral infection or alcohol use. Most HCCs are diagnosed at a stage at which surgical resection is not feasible. Even in patients receiving surgery rates of recurrence and metastasis remain high. There are few effective HCC therapies and hence a need for novel, rational approaches to treatment. Platelet derived growth factor receptor-? (PDGFR-?) is involved in tumor angiogenesis and maintenance of the tumor microenvironment and has been implicated in development and metastasis of HCC. Objective: To examine PDGFR-α as a target for therapy of HCC and explore opportunities and strategies for PDGFR-α inhibition. Methods: A review of relevant literature. Results/conclusions: Targeted inhibition of PDGFR-α is a rational strategy for prevention and therapy of HCC.

Original languageEnglish (US)
Pages (from-to)443-454
Number of pages12
JournalExpert Opinion on Therapeutic Targets
Volume13
Issue number4
DOIs
StatePublished - Apr 2009

Fingerprint

Tumors
Hepatocellular Carcinoma
Platelet-Derived Growth Factor Receptors
Liver
Surgery
Alcohols
Neoplasm Metastasis
Therapeutics
Tumor Microenvironment
Virus Diseases
Maintenance
Recurrence
Wounds and Injuries
Neoplasms

Keywords

  • FGF
  • HCC
  • Heparinase
  • Hepatocarcinogenesis
  • PDGF
  • Receptor tyrosine kinase
  • SULF1
  • SULF2
  • VEGF

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

PDGFRα : A new therapeutic target in the treatment of hepatocellular carcinoma? / Oseini, Abdul M.; Roberts, Lewis Rowland.

In: Expert Opinion on Therapeutic Targets, Vol. 13, No. 4, 04.2009, p. 443-454.

Research output: Contribution to journalArticle

@article{19c1fa4077ea4670a9e1fd89ed20a460,
title = "PDGFRα: A new therapeutic target in the treatment of hepatocellular carcinoma?",
abstract = "Background: Hepatocellular carcinoma (HCC) develops most often in a background of chronic inflammatory liver injury from viral infection or alcohol use. Most HCCs are diagnosed at a stage at which surgical resection is not feasible. Even in patients receiving surgery rates of recurrence and metastasis remain high. There are few effective HCC therapies and hence a need for novel, rational approaches to treatment. Platelet derived growth factor receptor-? (PDGFR-?) is involved in tumor angiogenesis and maintenance of the tumor microenvironment and has been implicated in development and metastasis of HCC. Objective: To examine PDGFR-α as a target for therapy of HCC and explore opportunities and strategies for PDGFR-α inhibition. Methods: A review of relevant literature. Results/conclusions: Targeted inhibition of PDGFR-α is a rational strategy for prevention and therapy of HCC.",
keywords = "FGF, HCC, Heparinase, Hepatocarcinogenesis, PDGF, Receptor tyrosine kinase, SULF1, SULF2, VEGF",
author = "Oseini, {Abdul M.} and Roberts, {Lewis Rowland}",
year = "2009",
month = "4",
doi = "10.1517/14728220902719233",
language = "English (US)",
volume = "13",
pages = "443--454",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - PDGFRα

T2 - A new therapeutic target in the treatment of hepatocellular carcinoma?

AU - Oseini, Abdul M.

AU - Roberts, Lewis Rowland

PY - 2009/4

Y1 - 2009/4

N2 - Background: Hepatocellular carcinoma (HCC) develops most often in a background of chronic inflammatory liver injury from viral infection or alcohol use. Most HCCs are diagnosed at a stage at which surgical resection is not feasible. Even in patients receiving surgery rates of recurrence and metastasis remain high. There are few effective HCC therapies and hence a need for novel, rational approaches to treatment. Platelet derived growth factor receptor-? (PDGFR-?) is involved in tumor angiogenesis and maintenance of the tumor microenvironment and has been implicated in development and metastasis of HCC. Objective: To examine PDGFR-α as a target for therapy of HCC and explore opportunities and strategies for PDGFR-α inhibition. Methods: A review of relevant literature. Results/conclusions: Targeted inhibition of PDGFR-α is a rational strategy for prevention and therapy of HCC.

AB - Background: Hepatocellular carcinoma (HCC) develops most often in a background of chronic inflammatory liver injury from viral infection or alcohol use. Most HCCs are diagnosed at a stage at which surgical resection is not feasible. Even in patients receiving surgery rates of recurrence and metastasis remain high. There are few effective HCC therapies and hence a need for novel, rational approaches to treatment. Platelet derived growth factor receptor-? (PDGFR-?) is involved in tumor angiogenesis and maintenance of the tumor microenvironment and has been implicated in development and metastasis of HCC. Objective: To examine PDGFR-α as a target for therapy of HCC and explore opportunities and strategies for PDGFR-α inhibition. Methods: A review of relevant literature. Results/conclusions: Targeted inhibition of PDGFR-α is a rational strategy for prevention and therapy of HCC.

KW - FGF

KW - HCC

KW - Heparinase

KW - Hepatocarcinogenesis

KW - PDGF

KW - Receptor tyrosine kinase

KW - SULF1

KW - SULF2

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=67649219059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649219059&partnerID=8YFLogxK

U2 - 10.1517/14728220902719233

DO - 10.1517/14728220902719233

M3 - Article

C2 - 19335066

AN - SCOPUS:67649219059

VL - 13

SP - 443

EP - 454

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 4

ER -